DUBLIN – Medigene AG is getting a slice of the action from sales of Amgen Inc.’s pioneering oncolytic virus therapy Imlygic (talimogene laherparepvec), in an intellectual property licensing deal involving its spin-off company Catherex Inc., which Amgen is acquiring for $10.5 million up front plus regulatory and sales-based milestones, as well as single-digit royalty payments on Imlygic sales.